TW201806602A - Inflammation and sore resistant medicine for oral soft tissue (gum, mucous membrane) capable of having multiple efficacies in one medicine - Google Patents
Inflammation and sore resistant medicine for oral soft tissue (gum, mucous membrane) capable of having multiple efficacies in one medicine Download PDFInfo
- Publication number
- TW201806602A TW201806602A TW105127917A TW105127917A TW201806602A TW 201806602 A TW201806602 A TW 201806602A TW 105127917 A TW105127917 A TW 105127917A TW 105127917 A TW105127917 A TW 105127917A TW 201806602 A TW201806602 A TW 201806602A
- Authority
- TW
- Taiwan
- Prior art keywords
- aforementioned
- content
- inflammatory
- acid
- agent
- Prior art date
Links
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 27
- 210000004400 mucous membrane Anatomy 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 title abstract description 8
- 206010061218 Inflammation Diseases 0.000 title abstract description 4
- 230000004054 inflammatory process Effects 0.000 title abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 44
- 239000000654 additive Substances 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 239000002998 adhesive polymer Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 230000003023 adrenocorticotropic effect Effects 0.000 claims abstract description 6
- 239000005556 hormone Substances 0.000 claims abstract description 6
- 229940088597 hormone Drugs 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 26
- 230000000996 additive effect Effects 0.000 claims description 21
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 19
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 14
- 239000002562 thickening agent Substances 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 11
- 235000012239 silicon dioxide Nutrition 0.000 claims description 11
- 210000004877 mucosa Anatomy 0.000 claims description 10
- -1 silicate compound Chemical class 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 9
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 9
- 229940041616 menthol Drugs 0.000 claims description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 9
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 229960005150 glycerol Drugs 0.000 claims description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 8
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 7
- 239000005770 Eugenol Substances 0.000 claims description 7
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 7
- 229960002217 eugenol Drugs 0.000 claims description 7
- 230000008439 repair process Effects 0.000 claims description 7
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 5
- 101800000414 Corticotropin Proteins 0.000 claims description 5
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 5
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 5
- 229960000258 corticotropin Drugs 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 230000005923 long-lasting effect Effects 0.000 claims description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 229960003415 propylparaben Drugs 0.000 claims description 4
- 150000002222 fluorine compounds Chemical class 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 125000002168 glycyrrhetinic acid group Chemical group 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- YNZOICUNEVJUEJ-UHFFFAOYSA-N propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO YNZOICUNEVJUEJ-UHFFFAOYSA-N 0.000 claims 1
- 150000004760 silicates Chemical class 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 230000007774 longterm Effects 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910001868 water Inorganic materials 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 6
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229910004298 SiO 2 Inorganic materials 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 229960003720 enoxolone Drugs 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 235000019738 Limestone Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 239000006028 limestone Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 230000009965 odorless effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 229910021532 Calcite Inorganic materials 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000006389 Peri-Implantitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002528 anti-freeze Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000004579 marble Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-IDZWEYSVSA-N Liquiritic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-IDZWEYSVSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000003160 antidiuretic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本發明提供一種抗發炎酸痛劑之技術領域,尤指其技術上提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑。 The invention provides the technical field of an anti-inflammatory sore agent, in particular, it technically provides an anti-inflammatory sore agent for oral soft tissue (gingival, mucosa).
習知並沒有相同或近似於本發明者,茲舉一例也是用於口腔的習知專利說明。如其申請案號第102142948號「口內膠組成物套組之醫療用途」,其包含有漱口劑,該漱口劑成份包含水、碳酸氫鈉、糖精鈉以及微量之薄荷醇與食用色素藍色1號,口內凝膠劑於口腔中形成一保護口腔黏膜之薄膜,可減少外力刺激,藉此保護任何方式引起口腔潰瘍之黏膜,減緩黏膜因直接接觸而產生劇烈之疼痛感。其中,該口內凝劑係包含水、聚乙烯吡咯烷酮K-90、氯化鈣、甘草酸二鉀、苯扎氯銨、乙二胺四乙酸二鈉鹽、山梨酸鉀、以及丙二醇;並且,配合不同之成份比例,係可直接使用或加水稀釋使用,然聚乙烯吡咯烷酮K-90具有解毒、止血、提高溶解濃度、防止腹膜粘連、促進血沉等作用,為該習之專利之助溶劑,氯化鈣為一種導入劑,雖可加速骨骼牙齒鈣化,為 鈣化過度,反容易造成牙齒過度脆化,進而容易崩損,又藝會造成口腔肌肉過度異常活化,而造成神基肌肉失調,或軟弱無力,尤其對氯化鈣較為敏感者,較不適宜使用。而苯扎氯銨是經常使用的消毒劑,標準的使用濃度範圍為0.004%至0.01%,過多的濃度會產生腐蝕性,反而無法達到鎮定消炎之作用。而糖精鈉更可能有致癌之疑慮及風險。 The conventional knowledge is not the same or similar to the present inventor, and here is an example of the conventional patent specification for oral cavity. For example, its application No. 102142948 "Medical use of intraoral gum composition kit" includes mouthwash, which contains water, sodium bicarbonate, sodium saccharin, and trace amounts of menthol and food color blue No.1, the gel in the mouth forms a film to protect the oral mucosa in the oral cavity, which can reduce external stimuli, thereby protecting the mucous membranes that cause oral ulcers in any way, and slowing the severe pain caused by direct contact of the mucous membranes. Wherein the oral coagulant comprises water, polyvinylpyrrolidone K-90, calcium chloride, dipotassium glycyrrhizinate, benzalkonium chloride, disodium ethylenediaminetetraacetate, potassium sorbate, and propylene glycol; and, It can be used directly or diluted with water with different composition ratios. However, polyvinylpyrrolidone K-90 has the functions of detoxification, hemostasis, increase of dissolved concentration, prevention of peritoneal adhesion, and promotion of erythrocyte sedimentation. Calcium is an introduction agent, although it can accelerate calcification of bones and teeth, Excessive calcification can easily lead to excessive brittleness of the teeth, which can easily break down. It can also cause excessive activation of oral muscles, which can cause imbalance or weakness of the basal muscles, especially those who are more sensitive to calcium chloride and are not suitable for use. . However, benzalkonium chloride is a commonly used disinfectant, and the standard concentration range is 0.004% to 0.01%. Excessive concentration will cause corrosiveness, but it cannot achieve the effect of calming and anti-inflammatory. And saccharin sodium is more likely to cause cancer concerns and risks.
惟,前述習知前案,其係以兩劑的形式使用,且前述習知前案係作為口腔潰瘍的使用。而本發明為一劑的形式,本發明作為口腔軟組織(牙齦、黏膜)抗發炎酸痛用,本發明與習知並不相同。 However, the aforementioned previous case is used in the form of two doses, and the aforementioned prior case is used as an oral ulcer. The present invention is in the form of a dose. The present invention is used as an anti-inflammatory sore for oral soft tissues (gum, mucous membranes). The present invention is different from the conventional one.
是以,針對上述習知製劑所存在之問題點,如何開發一種更具理想實用性之創新製劑,實消費者所殷切企盼,亦係相關業者須努力研發突破之目標及方向。 Therefore, in view of the problems existing in the above-mentioned conventional preparations, how to develop an innovative preparation with more ideal practicability is eagerly awaited by consumers, and it is also the goal and direction for relevant industry players to work hard to make breakthroughs.
有鑑於此,發明人本於多年從事相關產品之製造開發與設計經驗,針對上述之目標,詳加設計與審慎評估後,終得一確具實用性之本發明。 In view of this, the inventor has been engaged in the manufacturing development and design of related products for many years. In view of the above-mentioned goals, after detailed design and careful evaluation, the present invention is indeed practical.
本發明之主要目的在於提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其包含一種以上促腎上腺皮質激素或抗炎抑制化合物、具長效黏附性之一種以上黏合聚合物、一種填補修護劑以及一種以上之添加劑混合而成一混合物;其中前述促腎上腺皮質激素或抗炎抑制化合物含 量為0.5~2質量百分比;前述黏合聚合物含量為1~4.5質量百分比;前述填補修護劑含量為35~45質量百分比;前述添加劑含量為30~50質量百分比,前述混合物的酸鹼值指數PH6~8.5。 The main object of the present invention is to provide an anti-inflammatory sore agent for oral soft tissues (gum, mucous membranes), which comprises one or more adrenocorticotropic hormones or anti-inflammatory inhibitory compounds, one or more adhesive polymers with long-lasting adhesion, and one kind of filling repair Agent and one or more additives into a mixture; wherein the aforementioned adrenocorticotropic hormone or anti-inflammatory inhibitory compound contains The content is 0.5 to 2 mass percent; the content of the aforementioned adhesive polymer is 1 to 4.5 mass percent; the content of the aforementioned filling and repairing agent is 35 to 45 mass percent; the content of the aforementioned additive is 30 to 50 mass percent; and the pH index of the mixture is PH6 ~ 8.5.
為達上述目的,本發明提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述促腎上腺皮質激素或抗炎抑制化合物包含選自3 β-羥基-11-氧-12-齊墩果烯-30-酸、(20 β)-3 β-羥基-11-氧奧利安-12-齊墩果烯-29-酸、(3 β,20 β)-3-羥基-11-氧-12-齊墩果烯-29-酸、去氧甘草次酸(deoxyglycyrrhetic acid)、18 β-甘草次酸、18-α-羥基甘草次酸(18-α-droxyglycyrrhetic acid)、二羥基甘草次酸(dihydroxyglycyrrhetic acid即grabric acid)及異甘草次酸(liquiritic acid)化合物所組成群組的其中之一或一種以上。 To achieve the above object, the present invention provides an anti-inflammatory sore agent for oral soft tissue (gingival, mucosa), wherein the aforementioned adrenocorticotropic hormone or anti-inflammatory inhibitory compound comprises a compound selected from 3 β-hydroxy-11-oxy-12-oleanolene -30-acid, (20 β) -3 β-hydroxy-11-oxyorion-12-oleanolene-29-acid, (3 β, 20 β) -3-hydroxy-11-oxy-12- Oleanene-29-acid, deoxyglycyrrhetic acid, 18 β-glycyrrhetic acid, 18-α-droxyglycyrrhetic acid, dihydroxyglycyrrhetic acid acid is one or more of the group consisting of grabric acid and liquiritic acid compounds.
為達上述目的,本發明提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述黏合聚合物包含有一增稠劑及一矽酸鹽類化合物,前述增稠劑為(Sodium Carboxymethyl Cellulose簡稱NaCMC)羧甲基纖維素鈉,前述增稠劑之含量為0.5~2.5質量百分比,前述矽酸鹽類化合物為(SiO2)二氧化矽,前述矽酸鹽類化合物之含量為0.5~2質量百分比。 In order to achieve the above object, the present invention provides an anti-inflammatory sore agent for oral soft tissue (gum, mucous membrane), wherein the adhesive polymer includes a thickener and a silicate compound, and the thickener is (Sodium Carboxymethyl Cellulose, referred to as NaCMC) ) Sodium carboxymethyl cellulose, the content of the thickener is 0.5 to 2.5 mass percent, the silicate compound is (SiO2) silicon dioxide, and the content of the silicate compound is 0.5 to 2 mass percent.
為達上述目的,本發明提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述填補修護劑為碳酸鈣 (CaCO3)。 In order to achieve the above object, the present invention provides an anti-inflammatory sore agent for oral soft tissues (gingival, mucosa), wherein the aforementioned filling and repairing agent is calcium carbonate (CaCO 3 ).
為達上述目的,本發明提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述添加劑可包含有propane-1,2,3-triol丙三醇(甘油)、(1R,2S,5R)-2-isopropyl-5-methylcyclohexanol(1R,2S,5R)-2-異丙醇-5-甲基環己醇(薄荷醇)及純水(Purified Water)之混合添加物,其中前述propane-1,2,3-triol丙三醇(甘油)之含量為30~40質量百分比;前述(1R,2S,5R)-2-isopropyl-5-methylcyclohexanol(1R,2S,5R)-2-異丙醇-5-甲基環己醇(薄荷醇)之含量為0.3~1.3質量百分比。 To achieve the above object, the present invention provides an anti-inflammatory sore agent for oral soft tissue (gingival, mucosa), wherein the aforementioned additives may include propane-1,2,3-triol glycerol (glycerin), (1R, 2S, 5R) -2-isopropyl-5-methylcyclohexanol (1R, 2S, 5R) -2-isopropyl-5-methylcyclohexanol (menthol) and mixed water (Purified Water) mixed additive, in which the aforementioned propane-1 The content of 2,3,3-triol glycerol (glycerin) is 30 to 40% by mass; the aforementioned (1R, 2S, 5R) -2-isopropyl-5-methylcyclohexanol (1R, 2S, 5R) -2-isopropanol The content of -5-methylcyclohexanol (menthol) is 0.3 to 1.3 mass percent.
為達上述目的,本發明提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述添加劑可包含一種以上之添加聚合物,前述添加聚合物包含4-烯丙基-2-甲氧基苯酚(Eugenol丁香酚)或對羥基苯甲酸丙酯(Propyl paraben)。 In order to achieve the above object, the present invention provides an anti-inflammatory sore agent for oral soft tissue (gum, mucous membrane), wherein the aforementioned additive may include more than one additive polymer, and the aforementioned additive polymer includes 4-allyl-2-methoxyphenol (Eugenol eugenol) or Propyl paraben.
為達上述目的,本發明提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述添加劑可包含月桂基硫酸鈉(Sodium Lauryl Sulfate),前述月桂基硫酸鈉(Sodium Lauryl Sulfate)含量為0.5~3.5質量百分比。 In order to achieve the above object, the present invention provides an anti-inflammatory sore agent for oral soft tissues (gum, mucous membranes), wherein the aforementioned additives may include sodium lauryl sulfate (Sodium Lauryl Sulfate), and the content of the aforementioned sodium lauryl sulfate is 0.5 ~ 3.5 mass percent.
為達上述目的,本發明提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述添加劑可包含氟化合物。 In order to achieve the above object, the present invention provides an anti-inflammatory sore agent for oral soft tissue (gingival, mucosa), wherein the aforementioned additive may include a fluorine compound.
有關本發明所採用之技術、手段及其功效,茲舉一較佳實施例並配合圖式詳細說明於後,相信本發明上述之目的、構造及特徵,當可由之得一深入而具體的瞭解。 Regarding the technology, means and effects adopted by the present invention, a preferred embodiment will be described in detail with reference to the drawings. It is believed that the above-mentioned objects, structures, and characteristics of the present invention can be understood thoroughly and in detail. .
本發明係提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑之設計者。 The invention provides a designer of an anti-inflammatory sore agent for oral soft tissues (gum, mucosa).
為使 貴審查委員對本發明之目的、特徵及功效能夠有更進一步之瞭解與認識,茲配合實施方式及圖式詳述如後:本發明提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,係包含有:一種以上促腎上腺皮質激素或抗炎抑制化合物、具長效黏附性之一種以上黏合聚合物、一種填補修護劑以及一種以上添加劑混合而成一混合物;其中前述促腎上腺皮質激素或抗炎抑制化合物含量為0.5~2質量百分比;前述黏合聚合物含量為1~4.5質量百分比;前述填補修護劑含量為35~45質量百分比;前述添加劑含量為30~50質量百分比,前述混合物的酸鹼值指數PH6~8.5。 In order to allow your reviewers to further understand and understand the purpose, features and effects of the present invention, the following detailed description is given in conjunction with the embodiments and drawings: The present invention provides an oral inflammatory soft tissue (gum, mucosa) anti-inflammatory sore agent, The system comprises: one or more adrenocorticotropic hormones or anti-inflammatory inhibitory compounds, one or more adhesive polymers with long-lasting adhesion, one filling repair agent and one or more additives; a mixture of the aforementioned adrenocorticotropic hormones or The content of the inflammation-inhibiting compound is 0.5 to 2% by mass; the content of the aforementioned adhesive polymer is 1 to 4.5% by mass; the content of the aforementioned filling and repairing agent is 35 to 45% by mass; the content of the aforementioned additive is 30 to 50% by mass; The base number index is PH6 ~ 8.5.
所述之一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述促腎上腺皮質激素或抗炎抑制化合物包含 選自3 β-羥基-11-氧-12-齊墩果烯-30-酸、(20 β)-3 β-羥基-11-氧奧利安-12-齊墩果烯-29-酸、(3 β,20 β)-3-羥基-11-氧-12-齊墩果烯-29-酸、去氧甘草次酸(deoxyglycyrrhetic acid)、18 β-甘草次酸、18-α-羥基甘草次酸(18-α-droxyglycyrrhetic acid)、二羥基甘草次酸(dihydroxyglycyrrhetic acid即grabric acid)及異甘草次酸(liquiritic acid)化合物所組成甘草次酸(Enoxolone)群組的其中之一或一種以上。 The oral soft tissue (gingival, mucosal) anti-inflammatory sore agent, wherein the aforementioned adrenocorticotropic hormone or anti-inflammatory inhibitory compound comprises Selected from 3 β-hydroxy-11-oxy-12-oleanolene-30-acid, (20 β) -3 β-hydroxy-11-oxolian-12-oleanolene-29-acid, ( 3 β, 20 β) -3-hydroxy-11-oxy-12-oleanolene-29-acid, deoxyglycyrrhetic acid, 18 β-glycyrrhetic acid, 18-α-hydroxyglycyrrhetin One or more of the Glycyrrhetinic acid (Enoxolone) group consisting of 18-α-droxyglycyrrhetic acid, dihydroxyglycyrrhetic acid (grabric acid) and liquiritic acid compound.
所述之一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述黏合聚合物包含有一增稠劑及一矽酸鹽類化合物,前述增稠劑為(Sodium Carboxymethyl Cellulose簡稱NaCMC)羧甲基纖維素鈉,前述增稠劑之含量為0.5~2.5質量百分比,前述矽酸鹽類化合物為(SiO2)二氧化矽,前述矽酸鹽類化合物之含量為0.5~2質量百分比。 The oral soft tissue (gingival, mucosal) anti-inflammatory sore agent, wherein the adhesive polymer includes a thickener and a silicate compound, and the thickener is (Sodium Carboxymethyl Cellulose (NaCMC)) carboxymethyl fiber The content of the thickener is 0.5 to 2.5 mass percent, the content of the silicate compound is (SiO 2 ) silicon dioxide, and the content of the aforementioned silicate compound is 0.5 to 2 mass percent.
所述之一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述填補修護劑為碳酸鈣(CaCO3)。 The oral soft tissue (gingival, mucosal) anti-inflammatory sore agent, wherein the aforementioned filling and repairing agent is calcium carbonate (CaCO 3 ).
所述之一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述添加劑可包含有propane-1,2,3-triol丙三醇(甘油)、(1R,2S,5R)-2-isopropyl-5-methylcyclohexanol(1R,2S,5R)-2-異丙醇-5-甲基環己醇(薄荷醇)及純水(Purified Water)之混合添加物,其中前述propane-1,2,3-triol丙三醇(甘油)之含量為30~40質量百分比;前述 (1R,2S,5R)-2-isopropyl-5-methylcyclohexanol(1R,2S,5R)-2-異丙醇-5-甲基環己醇(薄荷醇)之含量為0.3~1.3質量百分比。純水(Purified Water)為本發明濕度調節作用。 The oral soft tissue (gingival, mucosal) anti-inflammatory sore agent, wherein the aforementioned additive may include propane-1,2,3-triol glycerol (glycerin), (1R, 2S, 5R) -2-isopropyl- 5-methylcyclohexanol (1R, 2S, 5R) -2-isopropanol-5-methylcyclohexanol (menthol) and mixed water (Purified Water) mixed additive, wherein the aforementioned propane-1,2,3- The content of triol glycerol (glycerin) is 30 to 40 mass percent; The content of (1R, 2S, 5R) -2-isopropyl-5-methylcyclohexanol (1R, 2S, 5R) -2-isopropanol-5-methylcyclohexanol (menthol) is 0.3 to 1.3 mass percent. Purified Water is the humidity regulating effect of the present invention.
所述之一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述添加劑可包含一種以上之添加聚合物,前述添加聚合物包含4-烯丙基-2-甲氧基苯酚(Eugenol丁香酚)或對羥基苯甲酸丙酯(Propyl paraben)。 The oral soft tissue (gingival, mucosal) anti-inflammatory sore agent, wherein the aforementioned additive may include more than one additive polymer, and the aforementioned additive polymer includes 4-allyl-2-methoxyphenol (Eugenol eugenol) Or Propyl paraben.
所述之一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述添加劑可包含月桂基硫酸鈉(Sodium Lauryl Sulfate),前述月桂基硫酸鈉(Sodium Lauryl Sulfate)含量為0.5~3.5質量百分比。 The oral soft tissue (gingival, mucous membrane) anti-inflammatory sore agent, wherein the aforementioned additive may include Sodium Lauryl Sulfate, and the content of the aforementioned Sodium Lauryl Sulfate is 0.5 to 3.5 mass percent.
所述之一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其中前述添加劑可包含氟化合物。 The oral soft tissue (gingival, mucosal) anti-inflammatory sore agent, wherein the aforementioned additive may include a fluorine compound.
本發明主要可作為牙齦、口腔黏膜、植體周圍炎及牙周相關疾病症狀之修復、增生、消炎、殺菌、抗發炎等效果,其還具有抗病毒感染的作用,對致癌性的病毒如肝炎病毒,EB病毒及愛滋病毒的感染均有抑制作用,又與抗生素類之藥理即為相似,其用於治療葡萄球菌、鏈球菌、大腸桿菌、螺旋桿菌等的感染皆有程度上之效果產生。其化學結構與皮質固醇類相似。對切除腎上腺皮質及切除腦垂體的動物,甘草次酸仍能產生鈉瀦留及抗利尿和抗炎作用,即甘草次酸抑制了腎上腺皮質甾醇類在體內的破 壞,因而血液中皮質甾類含量相應增加,而呈現較明顯的腎上腺皮質激素樣作用,亦具有保泰松(苯丁唑啉)或氫化可的松樣的抗炎作用。對於棉球肉芽腫及甲醛性腳腫、皮下肉芽腫性炎症等均有抑製作用,其抗炎效價約為可的松或氫化可松的1/10,故其藥理性質對於牙齦、口腔黏膜、植體周圍炎及牙周等相關疾病症狀具有良好之抑制效果。 The invention can be mainly used for the restoration, hyperplasia, anti-inflammatory, bactericidal, anti-inflammatory and other effects of gum, oral mucosa, peri-implantitis, and periodontal-related diseases. It also has the effect of anti-viral infection and carcinogenic viruses such as hepatitis Virus, Epstein-Barr virus, and AIDS infections all have inhibitory effects, and are similar to antibiotics in their pharmacology. They are used to treat infections of Staphylococcus, Streptococcus, E. coli, Helicobacter, etc. to a certain extent. . Its chemical structure is similar to corticosteroids. Glycyrrhetic acid can still produce sodium retention and antidiuretic and anti-inflammatory effects in animals with adrenal cortex and pituitary resection, that is, glycyrrhetic acid inhibits the destruction of adrenal corticosteroids in the body. It is bad, so the content of corticosteroids in the blood increases correspondingly, and it shows a more obvious adrenocortical hormone-like effect, and also has anti-inflammatory effects of butapine (benzozoline) or hydrocortisone. It has inhibitory effects on cotton ball granulomas, formaldehyde-induced foot swelling, and subcutaneous granulomatous inflammation. Its anti-inflammatory potency is about 1/10 of cortisone or hydrocortisone, so its pharmacological properties are good for gums and oral mucosa , Peri-implantitis, periodontal and other related disease symptoms have a good inhibitory effect.
碳酸鈣(Calcium Carbonate)主要用於去漬、磨砂,填補牙本質小孔,是為一種抗敏、抗酸之填補劑。碳酸鈣是一種無機化合物,俗稱灰石、石灰石、石粉、大理石、方解石,是一種化合物,化學式是CaCO3,呈鹼性,基本上不溶於水,溶於酸。它是地球上常見物質,存在於霰石、方解石、白堊、石灰岩、大理石、石灰華等岩石內。或為動物骨骼或外殼的主要成分,亦是常用的鈣質來源,也常做為抑酸劑中的有效成分之一,因為其為鈣的來源,所以經研磨成粉末之後,在於除了對於牙齒表面之磨砂,去漬效果良好,可有效預防牙結石功效之外,更可因具填補牙本質小孔,將牙本質小孔完整覆蓋,可有效避免於牙本質小孔內的牙神經外露,而遭受冷熱食物刺激而感覺酸痛、酸軟。在於磨砂,去漬的同時,更因與(Sodium Carboxymethyl Cellulose簡稱NaCMC)羧甲基纖維素鈉及(SiO2)二氧化矽之黏合聚合物相聚和,可有效於牙本質小孔表面形成一層薄膜保護層,是為有效之抗敏、抗酸之填補 劑。 Calcium Carbonate is mainly used for removing stains and scrubs to fill the dentinal pores. It is an anti-allergy and acid-resistant filler. Calcium carbonate is an inorganic compound commonly known as limestone, limestone, stone powder, marble, and calcite. It is a compound with a chemical formula of CaCO 3. It is alkaline, basically insoluble in water, and soluble in acids. It is a common material on the earth and exists in rocks such as vermiculite, calcite, chalk, limestone, marble, and travertine. Or the main component of animal bones or shells. It is also a commonly used source of calcium. It is also often used as one of the active ingredients in acid suppressants. Because it is a source of calcium, after grinding into powder, The matte surface has a good stain removal effect, which can effectively prevent calculus. In addition, it can fill the dentinal pores and completely cover the dentinal pores. It can effectively avoid the exposure of the dental nerve in the dentinal pores. I feel sore and tender when I am stimulated by hot and cold food. It is frosted and stain-removed. At the same time, it is combined with the adhesive polymer of Sodium Carboxymethyl Cellulose (NaCMC) sodium carboxymethyl cellulose and (SiO 2 ) silicon dioxide. The protective layer is an effective anti-allergy and acid-resistant filler.
羧甲基纖維素鈉(Sodium Carboxymethyl Cellulose簡稱NaCMC)為纖維素羧甲基醚的鈉鹽,為白色或乳白色纖維狀粉末或顆粒,無臭、無味,具吸濕性。易於分散在水中成澄明膠狀液,在乙醇等有機溶媒中不溶。1%水溶液pH為6.5~8.5,當pH>10或<5時,膠漿粘度顯著降低,在pH7時性能最佳。對熱穩定,在20℃以下粘度迅速上升,45℃時變化較慢,80℃以上長時間加熱可使其膠體變性而粘度明顯下降。褐變溫度226~228℃,碳化溫度252~253℃。其為一種無臭、無味,具吸濕性。易於分散在水中成澄明膠狀液,在乙醇等有機溶媒中不溶。根據《食品安全國家標準、食品添加劑使用標準》(GB2760-2011)規定:在食品中作用增稠劑使用。羧甲基纖維素鈉(NaCMC)具有乳化分散劑、固體分散性、不易腐敗、生理上無害等不同尋常的和極有價值的綜合物理、化學性質,是纖維素醚類中產量最大的、用途最廣、使用最為方便的產品,俗稱「工業味精」重要特性是形成高粘度的膠體、溶液、有粘著、增稠、流動、乳化分散、賦形、保水、保護膠體、薄膜成型、耐酸、耐鹽、懸濁等特性,且生理無害,因此在食品、醫藥、日化、石油、造紙、紡織、建築等領域得到廣泛應用。於本抗發炎酸痛劑中,為一種增稠劑,使提供藥劑附著之作用,並與二氧化矽(Silicone Dioxide)結合,使 其產生具一定之黏度,進而形成膠狀或膏狀之劑型。讓本藥劑可用於藥膏之塗抹,於患處形成保護薄膜狀,或牙膏狀態使用。 Sodium Carboxymethyl Cellulose (NaCMC for short) is the sodium salt of cellulose carboxymethyl ether. It is a white or milky white fibrous powder or granule, which is odorless, tasteless and hygroscopic. Easily dispersed in water to form a clear gelatinous liquid, insoluble in organic solvents such as ethanol. The pH of 1% aqueous solution is 6.5 ~ 8.5. When the pH is> 10 or <5, the viscosity of the glue is significantly reduced, and the performance is best at pH7. It is thermally stable, its viscosity rises rapidly below 20 ° C, and it changes slowly at 45 ° C. Long-term heating above 80 ° C can make its colloid denaturate and its viscosity drop significantly. The browning temperature is 226 ~ 228 ° C, and the carbonization temperature is 252 ~ 253 ° C. It is odorless, tasteless and hygroscopic. Easily dispersed in water to form a clear gelatinous liquid, insoluble in organic solvents such as ethanol. According to the "National Food Safety Standards, Standards for the Use of Food Additives" (GB2760-2011), thickeners are used in food. Carboxymethylcellulose sodium (NaCMC) has unusual and valuable comprehensive physical and chemical properties such as emulsifying and dispersing agents, solid dispersibility, not easy to spoil, and physiologically harmless. It is the largest yield and application of cellulose ethers. The most widely used and most convenient product, commonly known as "industrial monosodium glutamate" important characteristics are the formation of high-viscosity colloids, solutions, adhesion, thickening, flow, emulsification and dispersion, shaping, water retention, protective colloids, film forming, acid resistance, It is resistant to salt, turbidity, and physiologically harmless, so it is widely used in food, medicine, daily chemical, petroleum, paper, textile, construction and other fields. In this anti-inflammatory sore agent, it is a thickener, which provides the effect of drug attachment, and combines with Silicone Dioxide to make It produces a certain viscosity, and then forms a gel or paste. This medicine can be used to apply ointment, form a protective film on the affected area, or use in the state of toothpaste.
二氧化矽(Silicone Dioxide)為抗結塊劑與增稠劑。SiO2的網狀結構決定了它具有優良的物理和化學性質,加上SiO2在自然界的廣泛存在,從古到今都被人類廣泛地應用著。二氧化矽與其它化合物在高溫下熔融,快速冷卻可以製得玻璃。它也是沙子和石英的主要成分。在半導體和太陽能板等應用中,是目前主要的原料,於食品工業用作抗結劑,屬食品添加劑之列,是為防止食物和食物之間,或食物和包裝之間黏著。可能添加在任何的粉狀調味料、沖泡包、食鹽、切片乳酪等。因為此種礦物性粉末極細,有潤滑的效果。所以可以保持粉末類維持疏鬆的狀態而不結塊,另,其在醫學上的功能為交聯劑,可提供強度、靈活性,使膠原蛋白和結締組織附有彈性,二氧化矽在研究中被證實可以在骨骼、動脈壁、皮膚、牙齒、牙齦、頭髮和指甲中完整性的發揮作用,並被用於緩解濕疹和牛皮癬。研究目前正在確定二氧化矽對於風濕性疾病和動脈疾病中有無作用。二氧化矽可以防止骨質疏鬆症,強化肌肉骨骼系統,因此可以避免很多傷害,它也可以加速骨折的癒合,二氧化矽能幫助結構基體的形成和修復結締組織,礦物質在基體的堆積是有助於人體的成長。二氧化矽是根本 ,在成骨細胞中它負責鈣的沉積和骨骼的磷酸鹽蛋白基質。經研究顯示,骨骼疾病如軟骨病(軟骨)和骨質疏鬆症(或自發性骨折),雖然是鈣的不足所引起,但不能單一以鈣為主做治療。鈣加上二氧化矽,效果良好,故,配合碳酸鈣,對牙本質小孔之填補,或在表面形成保護層之效果都有優異的抗敏、抗酸的表現。 Silicone Dioxide is an anti-caking agent and thickener. The network structure of SiO 2 determines that it has excellent physical and chemical properties. In addition, the widespread presence of SiO 2 in nature has been widely used by humans from ancient times to the present. Silicon dioxide and other compounds are melted at high temperatures and rapidly cooled to make glass. It is also the main constituent of sand and quartz. It is currently the main raw material in applications such as semiconductors and solar panels. It is used as an anti-caking agent in the food industry and belongs to the category of food additives. It is used to prevent adhesion between food and food or between food and packaging. May be added to any powdered seasoning, brewing bag, salt, sliced cheese, etc. Because this mineral powder is extremely fine, it has a lubricating effect. Therefore, the powder can be maintained in a loose state without agglomeration. In addition, its medical function is a cross-linking agent, which can provide strength and flexibility to make collagen and connective tissue elastic. Silicon dioxide is being studied. It has been shown to play an integral role in bones, arterial walls, skin, teeth, gums, hair and nails and is used to relieve eczema and psoriasis. Research is currently determining the role of silica in rheumatic and arterial disease. Silicon dioxide can prevent osteoporosis and strengthen the musculoskeletal system, so it can avoid many injuries. It can also accelerate the healing of fractures. Silicon dioxide can help the formation of structural matrix and repair connective tissue. The accumulation of minerals in the matrix is Helps the growth of the human body. Silicon dioxide is fundamental, in osteoblasts it is responsible for calcium deposition and the phosphoprotein matrix of the bone. Studies have shown that skeletal diseases such as osteochondrosis (cartilage) and osteoporosis (or spontaneous fractures), although caused by insufficient calcium, cannot be treated with calcium alone. Calcium plus silicon dioxide has a good effect. Therefore, with calcium carbonate, it has excellent anti-sensitivity and acid resistance in filling dentin pores or forming a protective layer on the surface.
丙三醇(propane-1,2,3-triol)即是甘油(Glycerin),為一種保水劑與防凍劑。丙三醇是甘油三酯分子的骨架成分。當人體攝入食用脂肪時,其中的甘油三酯經過體內代謝分解,形成甘油並儲存在脂肪細胞中。因此,甘油三酯代謝的最終產物便是甘油和脂肪酸。可用作溶劑,潤滑劑,藥劑和甜味劑,其為無色無臭有甜味的粘稠液體,比重1.2613(20/4°),沸點290℃。可與水以任何比例混溶,有極大的吸濕性,稍溶于乙醇和乙醚,不溶于氯仿。甘油可用于制造硝化甘油,醇酸樹脂等。也可用作飛機和汽車液體燃料的抗凍劑,玻璃,紙的增塑劑以及化妝品、皮革、煙草、紡織品等的吸濕劑。在實驗室中可用以保存標本,其本身具有甜味,可於口腔患部塗抹時,具有良好的口感及潤滑感。 Glycerin (propane-1,2,3-triol) is glycerin, which is a water retaining agent and antifreeze. Glycerol is the backbone component of triglyceride molecules. When the human body consumes edible fat, the triglycerides in it are metabolized in the body to form glycerol and stored in fat cells. Therefore, the final products of triglyceride metabolism are glycerol and fatty acids. It can be used as solvents, lubricants, medicaments and sweeteners. It is a colorless, odorless, sweet, viscous liquid with a specific gravity of 1.2613 (20/4 °) and a boiling point of 290 ° C. It can be miscible with water in any proportion, has great hygroscopicity, slightly soluble in ethanol and ether, and insoluble in chloroform. Glycerin can be used to make nitroglycerin, alkyd resin, etc. It can also be used as an antifreeze for aircraft and automobile liquid fuels, plasticizers for glass and paper, and hygroscopic agents for cosmetics, leather, tobacco, and textiles. It can be used to preserve specimens in the laboratory. It has a sweet taste and can have a good taste and lubricity when applied to the affected part of the oral cavity.
(1R,2S,5R)-2-異丙醇-5-甲基環己醇即是Menthol薄荷醇:清涼、鎮定,使口氣清新、消臭。薄荷醇是在薄荷葉片裡製造的,也就是薄荷油的主要成分,是環 類單萜的一種。是植物所產生的高揮發性精油,其成份多為半萜、單萜及倍半萜,尤其在氣候溫暖時產量更高。某些重要的植物色素是類萜或含類萜基的化合物。其具有止癢、止痛、防腐、刺激、麻醉、清涼和抗炎作用,可治頭痛、神經痛、瘙癢及呼吸道炎症、萎縮性鼻炎、聲啞等,又可消除異味,使本劑可以提升其舒適感。 (1R, 2S, 5R) -2-isopropanol-5-methylcyclohexanol is Menthol menthol: it is cool, calm, refreshes the breath and deodorizes. Menthol is made in the leaves of mint, which is the main component of peppermint oil. A monoterpenoid. It is a highly volatile essential oil produced by plants. Its components are mostly semiterpenes, monoterpenes and sesquiterpenes, and its yield is higher especially in warm climates. Some important plant pigments are terpenoids or terpenoid-containing compounds. It has antipruritic, analgesic, antiseptic, irritating, narcotic, cooling and anti-inflammatory effects. It can cure headaches, neuralgia, pruritus and inflammation of the respiratory tract, atrophic rhinitis, hoarseness, etc., and can eliminate odors, so that this agent can enhance its comfortability.
4-烯丙基-2-甲氧基苯酚即是Eugenol丁香酚:是一種有機化合物,存在於多種植物中,富含於其精油中,如月桂油等。具有持久香氣,常作為香皂的香料。無色至淡黃色微稠厚液體,具強烈丁香氣味,主要用於抗菌,降血壓、局部麻醉藥,也用於製造香水、香精、精油、修飾劑和定香劑。可於本劑用來作為與主劑甘草次酸搭配,達到快速消炎、抗菌之效果,又本身具有局部麻醉之特性,可使口腔軟組織(牙齦、黏膜)迅速感到舒緩、鎮痛之效果。又可用於齲齒,且兼有局部防腐作用,是為增快功效,及增加舒適體感的最佳的添加劑之一。 4-Allyl-2-methoxyphenol is Eugenol Eugenol: it is an organic compound that exists in many plants and is rich in its essential oils, such as laurel oil. Has a long-lasting aroma and is often used as a perfume for soap. Colorless to pale yellow slightly thick liquid with strong lilac odor. It is mainly used for antibacterial, lowering blood pressure and local anesthetics. It is also used to make perfumes, fragrances, essential oils, modifiers and fixatives. It can be used in combination with the main agent glycyrrhetic acid to achieve rapid anti-inflammatory and antibacterial effects. It also has the characteristics of local anesthesia, which can make oral soft tissues (gum, mucosa) feel soothing and analgesic quickly. It can also be used for dental caries, and it also has local antiseptic effect. It is one of the best additives to increase efficacy and increase comfort and body feel.
對羥基苯甲酸丙酯(Propyl paraben)是一類用在化妝品及藥品工業中的防腐劑,也常用在食品添加劑中,它的鹽及化合物最初則用作殺細菌及殺真菌劑。在洗髮水、商業潤膚膏、刮鬍膏、人體潤滑劑、外用藥品、噴霧溶劑、化妝品和牙膏中均常用到此類化合物。其對於黴菌、酵母與細菌有廣泛的抗菌作用。使本劑提高其防腐能力和 溶解性。 Propyl paraben is a type of preservative used in the cosmetics and pharmaceutical industries. It is also commonly used in food additives. Its salts and compounds were originally used as bactericides and fungicides. These compounds are commonly used in shampoos, commercial body creams, shaving creams, human lubricants, topical medicines, spray solvents, cosmetics and toothpastes. It has a wide range of antibacterial effects against mold, yeast and bacteria. Make this agent improve its antiseptic ability and Solubility.
月桂基硫酸鈉(Sodium Lauryl Sulfate)又名十二烷基硫酸鈉(Sodium dodecyl sulfate),為常用的表面活性劑之一,是一種陰離子表面活性劑,屬於硫酸酯類表面活性劑的典型代表,微溶於醇,不溶於氯仿、醚,易溶於水,與陰離子、非離子復配伍性好,具有良好的乳化性、起泡性、發泡、滲透、去污和分散性能、泡沬豐富,生物降解快,被廣泛應用於牙膏、肥皂、沐浴乳、洗髮精、洗衣粉,以及化妝品中的發泡劑。可於本劑用來作為與填補修護劑之碳酸鈣之去漬、清潔之補強作用,使口腔之穢物清除後,讓填補修護劑之碳酸鈣得以修補及保護之作用。 Sodium Lauryl Sulfate, also known as Sodium dodecyl sulfate, is one of the commonly used surfactants, is an anionic surfactant, and is a typical representative of sulfate surfactants. Slightly soluble in alcohol, insoluble in chloroform and ether, easily soluble in water, good compatibility with anions and non-ions, good emulsification, foaming, foaming, penetration, decontamination and dispersion properties, rich foaming Fast biodegradation, widely used in toothpaste, soap, bath milk, shampoo, washing powder, and foaming agent in cosmetics. It can be used as a degreasing and cleaning effect with the calcium carbonate filling repair agent, so that after removing the oral cavity dirt, it can repair and protect the calcium carbonate filling repair agent.
前文係針對本發明之較佳實施例為本發明之技術特徵進行具體之說明;惟,熟悉此項技術之人士當可在不脫離本發明之精神與原則下對本發明進行變更與修改,而該等變更與修改,皆應涵蓋於如下申請專利範圍所界定之範疇中。 The foregoing is a detailed description of the technical features of the present invention with reference to the preferred embodiments of the present invention; however, those skilled in the art can make changes and modifications to the present invention without departing from the spirit and principles of the present invention, and the Such changes and modifications shall all be covered by the scope defined by the scope of patent application below.
綜上所述,本發明係提供一種口腔軟組織(牙齦、黏膜)抗發炎酸痛劑,其確已達到本發明之所有目的,另其組合結構之空間型態未見於同類產品,亦未曾公開於申請前,已符合專利法之規定,爰依法提出申請。 In summary, the present invention provides an anti-inflammatory sore agent for oral soft tissues (gum, mucous membranes), which has indeed achieved all the purposes of the present invention. In addition, the spatial configuration of its combined structure has not been seen in similar products and has not been disclosed in the application. Before, it had already met the requirements of the Patent Law, and filed an application in accordance with the law.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105127917A TW201806602A (en) | 2016-08-30 | 2016-08-30 | Inflammation and sore resistant medicine for oral soft tissue (gum, mucous membrane) capable of having multiple efficacies in one medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105127917A TW201806602A (en) | 2016-08-30 | 2016-08-30 | Inflammation and sore resistant medicine for oral soft tissue (gum, mucous membrane) capable of having multiple efficacies in one medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201806602A true TW201806602A (en) | 2018-03-01 |
Family
ID=62189643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105127917A TW201806602A (en) | 2016-08-30 | 2016-08-30 | Inflammation and sore resistant medicine for oral soft tissue (gum, mucous membrane) capable of having multiple efficacies in one medicine |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW201806602A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023066184A1 (en) | 2021-10-20 | 2023-04-27 | 庄国昇 | Use of oligopeptide in treatment of gingival inflammation, gingival atrophy and oral mucosa repair |
-
2016
- 2016-08-30 TW TW105127917A patent/TW201806602A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023066184A1 (en) | 2021-10-20 | 2023-04-27 | 庄国昇 | Use of oligopeptide in treatment of gingival inflammation, gingival atrophy and oral mucosa repair |
| US12383598B2 (en) | 2021-10-20 | 2025-08-12 | Advanced Healthtech Biopeptide Laboratories Co., Ltd | Method for treating gingivitis and gingival atrophy and repairing oral mucosa |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2842454C (en) | Nasal spray | |
| CN102342993B (en) | Anti-sensitization and restoration external preparation for skin | |
| JP2005504109A5 (en) | ||
| JPH09507072A (en) | Ethanol substitute | |
| JP2005504109A (en) | Composition for alleviating xerostomia and treating related diseases | |
| JP6522877B2 (en) | Oral composition | |
| BR112017013730B1 (en) | biphasic mouthwash, method for treating dry mouth, method for preparing a biphasic mouthwash and use of a hydrophilic phase and a hydrophobic phase | |
| US20110217246A1 (en) | Denture care composition | |
| CN104473822A (en) | Mouthwash tablet containing plant extract and preparation method thereof | |
| CN101735898A (en) | Indigowoad root liquid soap and production method thereof | |
| CN108938501A (en) | Chinese medicine composition and oral care product applied to oral care product | |
| CN102861206A (en) | Sterilizing and disinfecting aerosol for skin mucous membrane and preparation method thereof | |
| JP6903411B2 (en) | Topical composition | |
| CN105748356B (en) | A kind of compound Artemisia rupestris bitter taste toothpaste | |
| TW201806602A (en) | Inflammation and sore resistant medicine for oral soft tissue (gum, mucous membrane) capable of having multiple efficacies in one medicine | |
| JP5191156B2 (en) | Composition for external use | |
| US20080145461A1 (en) | Formulation and method of making a topical pain relief composition | |
| CN108853487A (en) | A kind of oral nursing liquid and preparation method thereof for treating canker sore | |
| JP2009503062A (en) | Composition, package and process for reducing malrubin and snoring | |
| CN107802641A (en) | Anti-inflammatory and anti-ache agent for oral soft tissue (gum, mucosa) | |
| CN108096105A (en) | A kind of potent hemostasis, eliminating dampness and heat toothpaste and preparation method thereof | |
| CN107184492A (en) | Health-care toothpaste and preparation method thereof | |
| RU2712085C1 (en) | Oral care means | |
| CN111700825B (en) | Oily composition for oral health care, preparation method and application thereof | |
| CN110522676A (en) | A kind of natural essential oil toothpaste formula and preparation method thereof |